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Objective: To assess the impact of patient cost-sharing for antihypertensive medications on 
the proportion of days covered (PDC) by antihypertensive medications, medical utilization, 
and health care expenditures among commercially insured individuals assigned to different 
risk categories.
Methods: Participants were identified from the Consolidated Health Cost Guidelines (CHCG) 
database (January 1, 2006–December 31, 2008) based on a diagnosis (index) claim for hyper-
tension, continuous enrollment $12 months pre- and post-index, and no prior claims for anti-
hypertensive medications. Participants were assigned to: low-risk group (no comorbidities), 
high-risk group (1+ selected comorbidities), or very high-risk group (prior hospitalization for 
1+ selected comorbidities). The relationship between patient cost sharing and PDC by antihy-
pertensive medications was assessed using standard linear regression models, controlling for 
risk group membership, and various demographic and clinical factors. The relationship between 
PDC and health care service utilization was subsequently examined using negative binomial 
regression models.
Results: Of the 28,688 study patients, 66% were low risk. The multivariate regression model 
supported a relationship between patient cost sharing per 30-day fill and PDC in the following 
year. For every US$1.00 increase in cost sharing, PDC decreased by 1.1 days (P , 0.0001). 
Significant predictors of PDC included high risk, older age, gender, Charlson Comorbidity 
Index score, geography, and total post-index insurer- and patient-paid costs. An increase in PDC 
was associated with a decrease in all-cause and hypertension-related inpatient, outpatient, and 
emergency room visits and medical, pharmacy, and total costs.
Conclusions: The trend has been for managed care organizations and employers to require 
patients to bear a greater out-of-pocket burden for health care resources consumed. This study 
illustrates the potential adverse effects of higher patient cost sharing among patients with hyper-
tension stratified by different risk levels. A decrease in PDC was predictive of higher resource 
utilization and health care costs, which should be of interest to payers and employers alike.
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Background
The Centers for Disease Control and Prevention estimates that one in three 
US adults has hypertension,1,2 and Framingham data estimate that 90% of non-
  hypertensive individuals aged 55 years or older will eventually develop hypertension 
in their   lifetime.3 Costs in terms of health care services, medication, and reduced 
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  productivity totaled US$76.6 billion for hypertension in 
the US in 2010.4 Although a variety of evidence-based 
medications are   available for the treatment and control of 
hypertension, these drugs will be ineffective if patients do 
not adhere to their prescribed regimens. Poor adherence to 
antihypertensive medication has been linked to poor blood 
pressure control, rehospitalization, and increased health 
care resource utilization. On the other hand, increased 
adherence to antihypertensive medication has been shown 
to reduce hospitalization risk and health care costs, and 
is therefore likely to decrease productivity loss due to 
chronic conditions.5
The management of hypertension presents an interesting 
challenge for the following reasons: (1) there are multiple 
drug classes available to treat the disease ranging from 
inexpensive diuretics to brand-name combination therapies 
and the newer direct renin inhibitors; (2) hypertension is a 
major independent risk factor for several comorbid condi-
tions, namely coronary artery disease, chronic kidney disease, 
diabetes, and ischemic stroke;6 (3) patients are generally on 
multiple medications to manage their hypertension, creating 
a financial burden due to out-of-pocket expenditures;7 and 
(4) as hypertension is an asymptomatic disease, adherence 
rates are low according to some estimates, ranging from 
36%–80%.8 Poor medication adherence among hyperten-
sive patients is one of the primary causes of the failure to 
achieve adequate control of blood pressure.9 The low rates 
of adherence to antihypertensive medication are mainly due 
to the complexity of dosing regimens and the side-effect 
profiles of the drugs,9 but poor adherence is also attributable 
to the asymptomatic nature of the disease, the fact that the 
condition is chronic, and the ensuing economic burden that 
many patients must share with third-party payers over the 
long term.10
As organizations grapple with the high cost of health 
care, policies to shift costs to patients have become the norm. 
In response, a body of literature has arisen that attempts to 
examine the impact of these cost shifts on outcomes. Since 
hypertension is a prevalent and chronic condition with a high 
cost burden, extensive research has been conducted to assess 
the impact of cost sharing on antihypertensive medication 
adherence.11–16 While the methods employed and popula-
tions examined vary widely, overwhelmingly these studies 
support a negative relationship between patient cost sharing 
in various forms and medication adherence. Chernew and 
colleagues12 found that medication adherence increased 
after copays were reduced for common antihypertensive 
medications. A 2010 study of military veterans found that a 
US$5 copayment increase (from US$2 to US$7) adversely 
impacted adherence to antihypertensive medications.13 In 
the same year, Maciejewski and colleagues examined the 
effects of eliminating copayments for generic medications 
and reducing copayments for brand-name medications, and 
found that adherence improved by 1.5 percentage points for 
patients with hypertension taking calcium-channel blockers.15 
Most recently, a retrospective study of employees of a large 
global pharmaceutical firm showed that reduced cost sharing 
was associated with increased medication adherence, with 
the greatest improvement observed among employees taking 
cardiovascular medications.14
Building upon previous research, this study assessed the 
impact of patient cost sharing in the form of 30-day copays for 
antihypertensive medications on proportion of days covered 
(PDC, used as the proxy for adherence) during the 12-month 
post-index period. Additionally, the impact of adherence 
to antihypertensive medications on medical utilization 
outcomes and health care expenditures for individuals with 
hypertension was assessed. The impetus for this research 
was an apparent gap in the literature, ie, no published study 
in this area applied an approach to stratify patients by “risk 
level” (as defined by measures of comorbidity) to determine 
whether risk level tempers or exacerbates the impact of cost 
sharing on adherence. This is an important aspect, given that 
comorbidity is often included as a covariate in similar studies 
in order to neutralize the independent effect of this variable on 
the outcome (adherence). By understanding how comorbidity 
risk level impacts the relationship between cost sharing and 
adherence, policy makers, health plans, and employers should 
be better positioned to create targeted policies.
Methods
Data source
Data for this study were obtained from the 2007 and 2008 
Consolidated Health Cost Guidelines database (CHCG) 
developed by Milliman.17 This database is used by Milliman 
to produce its Health Cost Guidelines tool used by payers 
nationwide to price health care benefits, set benchmarks, mea-
sure the impact of health plan changes, and manage health 
care utilization. It has also been used to conduct simulations 
that allow for estimation of the effects of health benefit 
modifications and evaluation of the risks and benefits of 
alternative benefit approaches. The current database contains 
medical, pharmacy, and enrollment data from 2004–2007 
for roughly 15 million patients, 2 million of whom had a 
diagnosis of hypertension at the time of the study sample 
identification period.
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Sample selection
In order to be included in the study, members were identified 
from the CHCG database based on the following criteria:
•	 $2 outpatient visits or $1 emergency room visit or $1 
hospitalization with hypertension as the primary or second-
ary International Classification of Diseases, Ninth Revision 
(ICD-9) code of 401xx, 402xx, 403xx, 404xx, or 405xx; and
•	 $12 months of continuous enrollment prior to the index 
diagnosis claim for hypertension (baseline period) and a 
minimum of 12 months of continuous enrollment follow-
ing the index diagnosis claim for hypertension (follow-up 
period); and
•	 No antihypertensive medication claims preceding the date 
of the first hypertension diagnosis; and
•	 At least one prescription for a hypertensive medication 
following the diagnosis for hypertension.
Primary outcome measures
Pharmacy-based outcome measures
The pharmacy-based measures consisted of annualized mea-
surements per member per year (PMPY) for: (a) the number 
of hypertension medications (any, brand, generic), and (b) 
medication adherence, defined as the PDC for antihypertensive 
medications. The PDC was calculated as the number of days 
with any antihypertensive medication divided by the number 
of days in the follow-up period for each patient.18 Use of refills 
for antihypertensive medications was determined using a set 
of rules to avoid double-counting covered days. For example, 
when a prescription for an antihypertensive medication was 
issued before the previous antihypertensive prescription should 
have run out, use of the new prescription was assumed to begin 
the day after the end of the old prescription and the days’ sup-
ply for the new prescription was appended to the end of the 
previous fill. Any surplus days’ supply remaining on the last 
day of the observation period was truncated. The PDC could 
only have a value between 0 and 1 and was multiplied by 100% 
to derive the percentage. On the basis of their PDC, patients 
were assigned an adherence value ranging from 0%–100%.
Medical utilization-based outcome measures
The number of hypertension-related emergency room visits, 
outpatient visits, and laboratory or diagnostic visits during 
the pre-index and post-index periods was determined for 
each patient.
Expenditure-based outcome measures
Expenditure-based measures consisted of health plan 
  pharmacy expenditures for antihypertensive medications, 
patient out-of-pocket costs for antihypertensive medications, 
and health plan expenditures for hypertension-related medi-
cal services for each of the three hypertension risk groups. 
Total health care and pharmacy expenditures for all services 
and prescriptions were computed in a similar manner.
Cohort assignment
Patients were assigned to one of the following risk groups 
based on the following criteria:
•	 Low risk: a diagnosis claim for hypertension but no 
comorbid conditions (see below) during the pre-index 
and post-index periods.
•	 High risk: a diagnosis claim for hypertension and a 
diagnosis claim for 1 or more comorbid conditions (see 
below) during the pre-index or post-index periods.
•	 Very high risk: a diagnosis claim for hypertension along 
with a hospitalization for 1 or more comorbid conditions 
(see below) during the pre-index or post-index periods.
The following comorbid conditions were applied in the 
categorization of risk groups:
–	 Diabetes (ICD-9 250xx)
–  Heart disease (ICD-9 410xx, 414xx)
–	 Chronic kidney disease (ICD-9 585xx, 586xx, 403xx, 
404xx)
–	 Ischemic stroke (ICD-9 430xx, 431xx, 432xx 433xx, 
434xx)
–  Depression (ICD-9 296xx, 311xx, 3004x)
–  Asthma (ICD-9 433xx, 440xx)
–  Pulmonary vascular disease (ICD-9 443xx)
–  Dyslipidemia (ICD-9 2724x).
Covariates
Covariates included in the regression models included 
age, gender, Charlson Comorbidity Index (CCI) score, 
geographic region of health plan enrollment, health insur-
ance plan type, income (based on assignment by zip code 
from the US Census Bureau), patient cost sharing for 
antihypertensive medications and hypertension-related 
medical services, and plan-paid medical expenditures for 
hypertension-related services.
Analysis: models
Models were created to evaluate treatment adherence 
(  measured as the number of days covered by a prescription 
for an antihypertensive medication in the year following 
diagnosis), health care service utilization (inpatient, ER, 
outpatient), and total allowed health care service cost 
(medical,   pharmaceutical, total cost). For the adherence 
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regressions, we used a standard linear regression. For the 
utilization   regressions, we used a zero-adjusted negative 
binomial model for lower frequency events and a negative 
binomial model for more frequent events. We considered 
Poisson models, but examination of the response variables 
showed that the binomial distribution provided a better 
description of the response variables. For costs, we created 
six models that predicted medical, pharmaceutical, and 
overall costs, both for hypertension-related services and all 
services. These regressions used a log-transformed response 
variable to produce a better fit.
Results
The characteristics of the overall sample and the defined 
risk groups are presented in Table 1. There were 28,688 
individuals who met the inclusion criteria, with the majority 
(66%) in the low-risk group (n = 18,937). The average age 
of the sample population was 49.5 years, with slightly fewer 
females (45.6%), and an estimated average annual income of 
US$41,964. The majority of the sample members resided in 
the South (36%) or Midwest (33.6%) and were enrolled in a 
preferred provider organization (PPO [76.5%]). By defini-
tion, the low-risk group did not have any members with the 
selected comorbidities, while in the very high-risk group, 
these conditions were prevalent (particularly dyslipidemia, 
diabetes, and heart disease). Patient cost-sharing and insurer-
paid costs for antihypertensive medications were identical, 
averaging US$96 per month. The mean number of distinct 
antihypertensive medications in the 12-month follow-up 
period was 1.38, with prescriptions for branded agents aver-
aging 1.73 and generics 5.75, respectively. The Charlson 
Comorbidity Index score was 0.58 across the overall sample, 
with the very high-risk group having the greatest comorbid-
ity burden, as expected. The average number of days over 
the 12-month follow-up period that patients in our study 
population received an antihypertensive drug (adherence) 
was 205 days (PDC 56%), with little difference between 
the three risk groups.
Characteristics of the study participants by risk group in 
terms of pre-index and post-index medication history and 
hypertension-related and all-cause health care expenditures 
(resources used, insurer-paid costs, and patient-paid costs) 
are shown in Table 2. With increasing risk, the number of 
medications, health care events, and costs increased. In 
most cases, both insurer-paid and patient-paid all-cause 
costs increased from the pre-index to post-index periods. 
Hypertension-related costs in the post-index period were 
mostly borne by the insurer, and were relatively low.
In order to determine the relationship between cost shar-
ing and adherence (ie, PDC), a multivariate regression model 
was constructed, controlling for the potential effects of factors 
that may have an independent relationship with adherence. 
Table 3 describes each covariate and offers the rationale 
for inclusion along with key supporting references. The 
full results of our model are presented in Table 4. For every 
US$1.00 increase in patient cost sharing per fill (30 days), 
the number of days in the year that a patient was covered 
by an antihypertensive medication decreased by 1.10 days 
(P , 0.0001). Risk group status was a significant predictor 
of adherence for those who were defined as “high risk” com-
pared to the reference “low risk” group. High-risk patients 
essentially were adherent for 7.78 more days (P , 0.0001). 
There was a general trend toward improved adherence with 
age, with the exception of the oldest group examined (ages 
56–65). Gender was a significant predictor of days adherent: 
males had approximately 3 fewer days of adherence compared 
with women (P = 0.045). The Charlson Comorbidity Index 
risk score also influenced adherence: for every point increase, 
adherence decreased by 6.23 days (P , 0.0001). Compared 
with residence in the western part of the US, residing in 
the South, Midwest, and Northeast was associated with a 
decrease in number of days adherent (P , 0.0001). Total 
costs paid by the insurer in both the pre-index and post-index 
periods were weakly associated with our dependent variable, 
as were total costs paid by the patient.
In an effort to further explore the relationship between 
the number of days patients were adherent to antihyperten-
sive medications and resource utilization in the 12-month 
post-index period, a series of eleven zero-inflated negative 
binomial regression models were constructed (data not 
shown). The dependent variables for these models included: 
all-cause and hypertension-related outpatient costs, all-
cause and hypertension-related inpatient costs, all-cause 
and hypertension-related pharmacy costs, all-cause and 
hypertension-related outpatient costs, ER utilization, total all-
cause and hypertension-related medical costs, total all-cause 
and hypertension-related pharmacy costs, total all-cause 
and hypertension-related medical plus pharmacy costs. The 
covariates included in each regression model were identical 
to those included in the previous models, which are fully 
described in Table 3. The results of this series of analyses 
suggest a beneficial association between the number of days 
patients were adherent to antihypertensive medication and 
economic outcomes. For example, the model which exam-
ined the impact of the number of days that patients were 
adherent to antihypertensive medication on total medical 
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Table 1 Sample characteristics
Low risk High risk Very high risk Overall
Number of persons, N (%) 18,937 (66.0%) 8057 (28.1%) 1694 (5.9%) 28,688
Average age, years 48.2 51.6 54.4 49.5
Female, N (%) 8979 (47.4%) 3512 (43.6%) 589 (34.8%) 13,080 (45.6%)
Average income, US$ $42,026 $41,907 $41,544 $41,964
Region of residence, N (%)
  Northeast 2301 (12.2%) 1155 (14.3%) 322 (19.0%) 3778 (13.2%)
  Midwest 6244 (33.0%) 2775 (34.4%) 617 (36.4%) 9636 (33.6%)
  South 6995 (36.9%) 2776 (34.5%) 565 (33.4%) 10,336 (36.0%)
  West 3397 (17.9%) 1351 (16.8%) 190 (11.2%) 4938 (17.2%)
Comorbid conditions, N (%)
  Diabetes 0 (0.0%) 2411 (29.9%) 586 (34.6%) 2997 (10.4%)
  Heart disease 0 (0.0%) 562 (7.0%) 781 (46.1%) 1343 (4.7%)
  Chronic kidney disease 0 (0.0%) 222 (2.8%) 107 (6.3%) 329 (1.1%)
  Ischemic stroke 0 (0.0%) 182 (2.3%) 350 (20.7%) 532 (1.9%)
  Depression N 0 (0.0%) 1314 (16.3%) 310 (18.3%) 1624 (5.7%)
  Atherosclerosis 0 (0.0%) 194 (2.4%) 206 (12.2%) 400 (1.4%)
  Peripheral vascular disease 0 (0.0%) 120 (1.5%) 87 (5.1%) 207 (0.7%)
  Dyslipidemia 0 (0.0%) 4734 (58.8%) 646 (38.1%) 5380 (18.8%)
Average antihypertensive medication costs paid by insurer $88 $111 $117 $96
Average antihypertensive medication costs paid by patient $93 $100 $103 $96
Number of distinct antihypertensive drugs 1.35 1.39 1.74 1.38
Average antihypertensive drug days per year 204 211 200 205
Average # brand name antihypertensive prescriptions 1.68 1.85 1.77 1.73
Average # generic antihypertensive prescriptions 5.61 5.81 7.05 5.75
Mean Charlson Comorbidity Index score 0.32 0.85 2.11 0.58
Health insurance plan type, N (%)
  Comprehensive major medical/traditional 1481 (7.8%) 706 (8.8%) 211 (12.5%) 2398 (8.4%)
  Point of service 900 (4.8%) 381 (4.7%) 60 (3.5%) 1341 (4.7%)
  Preferred provider organization 14,537 (76.8%) 6168 (76.6%) 1240 (73.2%) 21,945 (76.5%)
  Health maintenance organization 2019 (10.7%) 802 (10.0%) 183 (10.8%) 3004 (10.5%)
costs revealed that, on average, a 1-day increase in the total 
number of days adherent to antihypertensive medication was 
associated with a 0.13% decrease in total medical costs. The 
directionality of this relationship was similar for each model. 
An increase in the number of days adherent to antihyper-
tensive medication was associated with a decrease in both 
all-cause and hypertension-related utilization of inpatient, 
outpatient, and emergency room visits as well as medical, 
pharmacy, and total costs.
Discussion
As organizations grapple with the high cost of health care, 
programs and policies have been enacted in an attempt 
to reduce the burden. Policies enacted by payers include 
increasing patient copays and coinsurance for non-preferred 
or branded medications. More holistic approaches have been 
put into place by employers, and include reducing and/or 
eliminating patient copays for medications used to treat 
chronic conditions, the rationale being that, by promoting the 
use of these needed therapies, adherence will improve and 
patients will be less likely to require costly medical treatment 
down the road. This study supports that notion. Triggered by 
questions around the economic and clinical impact of these 
policies and programs, a body of literature now exists that 
effectively provides evidence of the benefits and challenges. 
Given the prevalence, chronicity, and economic impact of 
hypertension, many studies have been conducted to assess the 
impact of patient cost sharing specifically on antihypertensive 
medication adherence,11,12,15,16 while others have broadened 
the approach to target other cardiovascular conditions, such 
as diabetes.14
Recently, employers have been implementing creative 
strategies to improve the health of employees with chronic 
conditions and to rein in costs. “Value-based programs” and 
“value-based benefit design” are phrases used to describe 
these programs. The National Business Coalition on Health 
defines value-based benefit design as “the explicit use of 
employee benefit incentives to encourage people to adopt 
appropriate use of high-value health services, adopt healthy 
lifestyles, and select high performance providers.”19
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Table 2 Sample characteristics: medications, health care expenditures, and events
Low risk High risk Very high risk Overall
Total generic medications
Pre-index
  Total generic medications, pre index 3.18 4.32 4.62 3.59
    Total medication costs paid by insurer, pre-index $411 $772 $745 $532
    Total medication costs paid by patient, pre-index $146 $241 $246 $179
Post-index
    Total number of generic medications, post-index 6.20 8.09 11.12 7.02
    Total medication costs paid by insurer, post-index $762 $1386 $1996 $1010
    Total medication costs paid by patient, post-index $316 $498 $700 $390
All inpatient visits
Pre-index
  Annual events 0.06 0.08 0.38 0.08
  Insurer paid $517 $747 $6,111 $912
  Patient paid $52 $89 $323 $78
Post-index
  Annual events 0.14 0.19 1.39 0.23
  Insurer paid $1267 $1839 $20,826 $2583
  Patient paid $107 $145 $1009 $171
All emergency room visits
Pre-index
  Annual events 0.41 0.43 1.31 0.47
  Insurer paid $82 $89 $442 $106
  Patient paid $27 $29 $97 $32
Post-index
  Annual events 0.66 0.66 3.00 0.80
  Insurer paid $158 $180 $1162 $223
  Patient paid $47 $43 $233 $57
All outpatient visits
Pre-index
  Annual events 7.15 10.29 12.27 8.33
  Insurer paid $834 $1368 $1509 $1024
  Patient paid $221 $299 $347 $250
Post-index
  Annual events 13.51 17.86 31.88 15.82
  Insurer paid $1776 $2587 $5438 $2220
  Patient paid $434 $568 $735 $489
All laboratory/diagnostic tests
Pre-index
  Annual events 3.66 5.25 7.11 4.31
  Insurer paid $417 $543 $809 $475
  Patient paid $92 $122 $156 $104
Post-index
  Annual events 7.79 10.88 18.52 9.29
  Insurer paid $862 $1137 $2316 $1025
  Patient paid $178 $222 $290 $197
All other annual events
Pre-index
  Annual events 1.05 1.49 2.57 1.26
  Insurer paid $155 $216 $390 $186
  Patient paid $32 $42 $54 $36
Post-index
  Annual events 1.71 2.44 6.42 2.20
  Insurer paid $353 $520 $1537 $470
  Patient paid $55 $67 $139 $64
HTN inpatient visits, post- index
  Annual events 0.02 0.03 0.24 0.03
  Insurer paid $187 $311 $4591 $482
  Patient paid $14 $28 $194 $29
(Continued)
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Table 2 (Continued)
Low risk High risk Very high risk Overall
HTN emergency room visits, post-index
  Annual events 0.05 0.04 0.10 0.05
  Insurer paid $9 $6 $21 $8
  Patient paid $5 $3 $7 $4
HTN outpatient visits, post-index
  Annual events 3.76 3.98 3.72 3.82
  Insurer paid $288 $355 $438 $316
  Patient paid $98 $100 $92 $98
HTN laboratory/ diagnostic tests, post-index
  Annual events 1.99 2.48 2.15 2.14
  Insurer paid $105 $130 $178 $116
  Patient paid $32 $36 $42 $34
HTN other annual events, post-index
  Annual events 0.19 0.18 0.43 0.20
  Insurer paid $24 $33 $97 $30
  Patient paid $5 $5 $9 $5
Abbreviation: HTN, hypertension.
Table 3 Covariates in regression models
Variable Description Justification
Cost sharing Continuous variable in 2008 US dollars, patient  
cost sharing per 30-day fill
Cost sharing tiers may affect utilization  
and adherence to medications34
Risk group 3 groups†: very high risk, high risk, and low risk  
as the reference group
Risk of complications and medication 
adherence are often related and must  
be controlled for5
Gender Binary variable, male = 1, and female as the  
reference group
Gender may be related to adherence
Age 7 groups†: ,17, 18–25, 26–35, 36–45, 46–55,  
56–65, and .65 as the reference group
Adherence to medications may be  
age-related
Region 4 groups†: South, Midwest, Northeast, and West  
as the reference group
Demographic control variable
Medical costs paid by insurer Log of medical costs paid by insurer Share of medical costs is associated with  
decreased adherence levels35
Medical costs paid by patient Log of medical costs paid by patient Share of medical costs is associated with  
decreased adherence levels35
Charlson Comorbidity Index score Index score variable treated as a continuous  
variable
Serves as a proxy for severity of disease  
and may serve as a predictor for mortality36
Note: †All groups are mutually exclusive and exhaustive.
A value-based program enacted by Blue Cross Blue Shield 
of North Carolina eliminated generic medication copayments 
and reduced copayments from tier 3 to tier 2 pricing for brand-
name medications in eight therapeutic classes for the treatment 
of cardiovascular disease, including hypertension.13 Using a 
propensity-matched design, adherence improved for employ-
ees exposed to the program for medications for diabetes, 
hypertension, hyperlipidemia, and congestive heart failure. 
Chernew and colleagues12 evaluated the outcomes associated 
with another value-based program enacted by a large employer 
and found that   medication adherence increased after patient 
copays were reduced for medications in five classes (includ-
ing those commonly used to treat hypertension: angiotensin-
converting enzyme inhibitors, angiotensin receptor blockers, 
and beta blockers) within the context of a disease management 
program. Copays for generic medications were reduced from 
US$5 to US$0 and from US$25 to US$12.50 for preferred 
brand name medications, and from US$45 to US$22.50 for 
non-preferred medications. Holding the influence of the dis-
ease management program constant in their analysis, there 
was a clear positive effect of the intervention on adherence 
to antidiabetic agents, beta-blockers, and angiotensin convert-
ing enzyme (ACE) inhibitors/angiotensin receptor blockers 
(ARBs) (reducing nonadherence by 7%–14%).
The low adherence rate of 56% (205 days per year) 
that we observed in our patient sample corroborates 
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the low adherence rates typically seen with hyperten-
sive patients.20–22 The similar PDC among the three risk 
groups despite the differences in age, types of comorbid 
conditions, and Charlson comorbidity index score is 
probably attributable to the fact that all groups used a 
similar number of antihypertensive medications (range, 
1.34–1.74 per person) and thereby paid similar costs (range, 
US$93–US$103 per person).
No gold standard has been established for measuring 
patient adherence to medications.23–28 The reliability and 
validity of using prescription claims data to assess medica-
tion adherence have been demonstrated in numerous studies, 
and claims data have been shown to be more comprehen-
sive than documentation of prescription use in medical 
records.29–32 Furthermore, claims data are more acces-
sible and less expensive than other medication-adherence 
measurements.33
Similar to our study, the relationship between patient 
cost sharing and adherence has been examined in creative 
ways using payer claims databases, while others have used 
databases to evaluate the outcomes of more naturalistic 
situations. One such study compared medication adherence 
at four Veterans Affairs medical centers between veterans 
who were exempt from copayments and propensity-matched 
veterans who were not exempt.13 Over 3500 veterans with 
hypertension were included in the analysis. The authors 
reported that increasing copayments from US$2 to US$7 
had an adverse impact on adherence for veterans treated with 
antihypertensive medications. Yoon and Ettner11 conducted 
a cross-sectional study of 83,893 commercially insured 
patients with hypertension using claims data and evaluated 
the impact of cost sharing on adherence to antihypertensive 
drugs across varying adherence levels. They concluded from 
the results of their analyses that cost sharing (copayments 
or coinsurance) had a substantial negative association with 
adherence (as determined by medication possession ratio 
[MPR]) among patients with low adherence to their medi-
cation, but the association between cost sharing and higher 
adherence levels was weak.
Our study provides additional support for the relationship 
between patient cost sharing and adherence. We sought an 
approach not previously taken by creating risk groups and 
subsequently controlling the potentially confounding effect 
of risk group membership in our models. This also allowed 
us to examine the independent effect of risk group member-
ship on our outcomes to determine whether an association 
was present. The independent association between risk group 
membership and PDC by antihypertensive medication was 
positive and significant for those patients designated as “high 
risk” by 3 days. These patients not only had hypertension, 
they also had a diagnosis of coronary artery disease, chronic 
kidney disease, diabetes, or ischemic stroke. We also took our 
Table 4 Predictors of days adherent to antihypertensive medication
Variable Parameter estimate Standard error T value Prob . t
Intercept 214.54 4.76 45.01 ,0.0001
Cost sharing -1.10 0.06 -18.28 ,0.0001
High risk† 7.78 1.52 5.13 ,0.0001
Very high risk† -3.14 3.15 -1.00 0.319
Male§ -2.67 1.33 -2.01 0.045
Age group (years)‡
 # 17 -29.02 9.56 -3.03 0.002
  18–25 -20.81 6.29 -3.31 0.000
  26–35 -10.99 3.76 -2.92 0.004
  36–45 5.38 3.30 1.63 0.104
  46–55 19.19 3.19 6.01 ,0.0001
  56–65 16.18 3.25 4.97 ,0.0001
South* -57.52 1.97 -29.23 ,0.0001
Midwest* -36.26 1.93 -18.75 ,0.0001
Northeast* -39.06 2.41 -16.19 ,0.0001
Total paid by insurer, pre-index -0.28 0.39 -0.71 0.477
Total paid by patient, pre-index -0.87 0.46 -1.88 0.059
Total paid by insurer, post-index -2.85 0.47 -6.13 ,0.0001
Total paid by patient, post-index 1.25 0.58 2.16 0.030
Charlson Comorbidity Index score -6.23 0.80 -7.84 ,0.0001
Notes: †Reference group is the low-risk population; §reference group is female; ‡reference group is over the age of 65; *reference group is the West region.
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analysis a few steps further than what had previously been done 
in the literature by examining whether PDC (adherence) for 
antihypertensive medication had an effect on resource utiliza-
tion and health care expenditures. We found a negative and 
consistent relationship (decrease in PDC = increase in resource 
utilization and costs), which should be further evidence of the 
importance of adherence among patients with hypertension and 
of particular interest to employers and health plans.
Limitations inherent to claims-based analyses, as well as 
limitations specific to this study, must be taken into account 
when considering the results of the analyses. Claims data are 
collected for the purpose of payment and not research, and 
are subject to possible coding errors, undercoding, and cod-
ing for the purpose of ruling out a suspected disease rather 
than determining the actual disease. Furthermore, when using 
prescription claims data to study adherence to medication, it 
should be noted that a claim does not equate to proof that a 
medication was taken, or that it was taken as prescribed.
With regard to study-specific limitations, the variables used 
to define and categorize patients into risk groups were based 
on claims data with its inherent limitations and were vali-
dated with any clinical data that would be obtained only from 
medical records. Second, given the number of medications 
that hypertensive patients take (which on average was ∼2), our 
definition of adherence merely measured the number of days 
within the follow-up period that a patient was “covered” by an 
antihypertensive medication prescription, accounting for any 
overlaps for multiple medications. Thus, we were not able to 
report more standard measures such as the MPR.
Conclusion
This study assessed the impact of patient cost sharing for 
antihypertensive medications among commercially insured 
individuals assigned to different risk categories on the PDC 
by antihypertensive medications, medical utilization, and 
health care expenditures. We found an association between 
higher patient cost sharing and decreased PDC as well as a 
beneficial association between PDC and various economic 
outcomes. An increase in PDC was associated with a decrease 
in both all-cause and hypertension-related utilization of 
inpatient, outpatient, and emergency room visits as well 
as   medical, pharmacy, and total costs. The current study 
  illustrates the potential untoward effects of higher patient cost 
sharing among patients with hypertension. Furthermore, the 
study found that a decrease in PDC is predictive of higher 
resource utilization and health care costs, which should be 
of interest to payers and employers alike.
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